ADDERALL XR 5 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adderall Xr 5, and what generic alternatives are available?
Adderall Xr 5 is a drug marketed by Takeda Pharms Usa and is included in one NDA.
The generic ingredient in ADDERALL XR 5 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADDERALL XR 5?
- What are the global sales for ADDERALL XR 5?
- What is Average Wholesale Price for ADDERALL XR 5?
Summary for ADDERALL XR 5
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Clinical Trials: | 40 |
Patent Applications: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ADDERALL XR 5 at DailyMed |
![ADDERALL XR 5 drug patent expirations Drug patent expirations by year for ADDERALL XR 5](/p/graph/s/t/ADDERALL_XR_5-patent-expirations.png)
Recent Clinical Trials for ADDERALL XR 5
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Boston Children's Hospital | Phase 1 |
The Beckwith Institute | Phase 4 |
Eva Szigethy | Phase 4 |
Pharmacology for ADDERALL XR 5
Drug Class | Central Nervous System Stimulant |
Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for ADDERALL XR 5
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ADDERALL XR 5 | amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021303-005 | May 22, 2002 | AB1 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADDERALL XR 5
International Patents for ADDERALL XR 5
See the table below for patents covering ADDERALL XR 5 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 69940673 | ⤷ Sign Up | |
Australia | 1214500 | ⤷ Sign Up | |
Spain | 2323910 | ⤷ Sign Up | |
Canada | 2348090 | SYSTEME D'ADMINISTRATION DE MEDICAMENTS PAR DOSES PULSEES PAR VOIE ORALE (ORAL PULSED DOSE DRUG DELIVERY SYSTEM) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |